Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice

Journal of Clinical Investigation

Volumn 107, Issue 8, 2001, Pages 975-984

  Knowles, J W ^a   Esposito, G ^a   Mao, L ^a   Hagaman, J R ^a   Fox, J E ^a   Smithies, O ^a   Rockman, H A ^a   Maeda, N ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; ENALAPRIL; FUROSEMIDE; HYDRALAZINE; LOSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CONTROLLED STUDY; FEMALE; HEART FUNCTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HEART WORK; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0035063196     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI11273     Document Type: Article

References (63)

1. Physiology of natriuretic peptides
2. Role of atrial natriuretic factor in volume control
3. Physiological regulation of blood pressure and kidney function by guanylyl cyclase isoforms
4. Natriuretic peptides
5. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic pepride hormones in humans
6. Measurement and significance of circulating natriuretic peptides in cardiovascular disease
7. In vivo murine cardiac hypertrophy
8. Hormones and hemodynamics in heart failure
9. Divergent pathways mediate the induction of ANF transgenes in neonatal and hypertrophic ventricular myocardium
10. Depletion o f mitogen-activated protein kinase using an antisense oligodeoxynucleotide approach downregulates the phenylephrine-induced hypertrophic response in rat cardiac myocytes
11. The mitogen-activated protein kinase kinase MEK1 stimulates a pattern of gene expression typical of the hypertrophic phenotype in rat ventricular cardiomyocytes
12. Molecular characterization of the stretch-induced adaptation of cultured cardiac cells. An in vitro model of load-induced cardiac hypertrophy
13. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts
14. Atrial natriuretic polypeptide as a novel antigrowth factor of endothelial cells
15. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells
16. Mechanisms of natriuretic-peptide-induced growth inhibition of vascular smooth muscle cells
17. Expression of guanylyl cyclase-A/atrial natriuretic peptide receptor blocks the activation of protein kinase C in vascular smooth muscle cells. Role of cGMP and cGMP-dependent protein kinase
18. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes
19. Extracellular signal-regulated protein kinase activation is required for the anti-hypertrophic effect of atrial natriuretic factor in neonatal rat ventricular myocytes
20. Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes
21. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A
22. Elevated blood pressures in mice lacking endothelial nitric oxide synthase
23. A non-invasive computerized tail-cuff system for measuring blood pressure in mice
24. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy
25. Cellular and functional defects in a mouse model of heart failure
26. Cardiac overexpression of a G(q) inhibitor blocks induction of extracellular signal-regulated kinase and C-JunNH(2)-terminal kinase activity in in vivo pressure overload
27. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide
28. A genetic model defines the importance of the atrial natriuretic peptide receptor (guanylyl cyclase-A) in the regulation of kidney function
29. Clinical misconceptions dispelled by epidemiological research
30. Trends in the prevalence of hypertension, anti-hypertensive therapy, and left ventricular hypertrophy from 1950 to 1989
31. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiograpby substudy
32. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: Comparison of six antihypertensive agents. The department of veterans affairs cooperative study group on antihypertensive agents
33. Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy
34. Cardiac hypertrophy: Old concepts, new perspectives
35. Myosin heavy chain mRNA during the development and regression of myocardial hypertrophy
36. Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats
37. Renin-angiotensin system stimulates cardiac and renal disorders in Tsukuba hypertensive mice
38. Signaling pathways for cardiac hypertrophy and failure
39. Myocardial recruitment during ANF mRNA increase with volume overload in the rat
40. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy
41. Ventricular expression of atrial and brain natriuretic peptides in dilated cardiomyopathy. An immunohistocytochemical study of the endomyocardial biopsy specimens using specific monoclonal antibodies
42. Augmented expression of atrial natriuretic polypeptide gene in ventricle of human failing heart
43. ABC of heart failure
44. Cardiopulmonary responses to chronic hypoxia in transgenic mice that overexpress ANP
45. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension
46. Cardiac fibrosis in mice lacking brain natriuretic peptide
47. HRas-dependent pathways can activate morphological and generic markers of cardiac muscle cell hypertrophy
48. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family
49. Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells
50. Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases
51. Regression of left ventricular hypertrophy and prevention of left ventricular dys-function by capropril in the spontaneously hypertensive rat
52. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy
53. ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice
54. Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR
55. Effects of indapamide in rats with pressure overload left ventricular hypertrophy
56. Molecular effects of M17055, furosemide and thiazide on cardiac hypertrophy of spontaneously hypertensive rats
57. Lessons from rat models of hypertension: From Goldblatt to genetic engineering
58. Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats. Temporal regulation and spatial heterogeneity
59. Development of the cardiovascular system
60. Angiotensin II increases left ventricular mass without affecting myosin isoform mRNAs
61. Effect of long-term treatment with beta-blocker on cardiac hypertrophy in SHR
62. Cardiac hypertrophy and antihypertensive therapy
63. Functional deletion mutation of the 5′-flanking region of type A human natriuretic peptide receptor gene and its association with essential hypertension and left ventricular hypertrophy in the Japanese